Relay Therapeutics (RLAY) Cash & Equivalents (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Cash & Equivalents data on file, last reported at $204.6 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 118.71% year-over-year to $204.6 million in Q1 2026; TTM through Mar 2026 was $204.6 million, a 118.71% increase from a year earlier, with the FY2025 full-year figure at $84.0 million, down 32.4% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $204.6 million, up from $84.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for RLAY reached as high as $354.6 million in Q3 2022 and fell as low as $84.0 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $146.3 million across 5 years, with a median of $143.7 million in 2023.
• Across the five-year window, Cash & Equivalents plunged 58.57% in 2022 and soared 118.71% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $151.8 million in 2022, then dropped by 5.31% to $143.7 million in 2023, then decreased by 13.53% to $124.3 million in 2024, then slumped by 32.4% to $84.0 million in 2025, then surged by 143.51% to $204.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $204.6 million in Q1 2026, $84.0 million in Q4 2025, and $91.6 million in Q3 2025.